This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Brazilian Association of Pharmaceutical Companies (Interfarma) | |
|---|---|
| Name | Brazilian Association of Pharmaceutical Companies (Interfarma) |
| Native name | Associação Brasileira da Indústria de Pesquisa Farmacêutica |
| Formation | 1999 |
| Headquarters | São Paulo, Brazil |
| Region served | Brazil |
| Membership | multinational and domestic pharmaceutical companies |
| Leader title | President |
| Leader name | Marcelo Gualberto |
Brazilian Association of Pharmaceutical Companies (Interfarma) is a Brazilian trade association representing multinational and domestic pharmaceutical research and development companies active in Brazil. The association engages with Brazilian and international institutions such as Agência Nacional de Vigilância Sanitária, Ministry of Health (Brazil), and World Health Organization to shape policy, promote investment, and facilitate access to innovative medicines. Interfarma participates in public debates involving stakeholders like Supremo Tribunal Federal, National Congress of Brazil, and multinational corporations including Pfizer, Roche, and Novartis.
Founded in 1999, the association emerged amid reforms influenced by agreements between Brazil and international actors such as the World Trade Organization and parties to the Trade-Related Aspects of Intellectual Property Rights framework. Early activities intersected with legal and policy developments involving the Brazilian Unified Health System and institutions like Fiocruz and ANVISA. In the 2000s Interfarma expanded during presidencies of figures linked to the Brazilian pharmaceutical industry and economic measures under administrations involving Fernando Henrique Cardoso and Luiz Inácio Lula da Silva. The organization later engaged in litigation and legislative advocacy around intellectual property disputes similar to cases involving Merck and Gilead Sciences in global contexts.
Interfarma's stated mission aligns with objectives common to industry associations represented by entities such as the International Federation of Pharmaceutical Manufacturers & Associations and aims to foster research investment, regulatory certainty, and intellectual property protections. It emphasizes cooperation with institutions including Ministry of Science, Technology and Innovation (Brazil), Brazilian Development Bank, and academic centers like University of São Paulo to promote clinical research and technology transfer. The association frames objectives around expanding access to innovative therapies while advocating policy frameworks reflective of agreements like the Doha Declaration and standards seen in jurisdictions such as the European Medicines Agency.
Membership comprises subsidiaries and affiliates of multinational corporations and national firms with profiles comparable to AstraZeneca, Bristol-Myers Squibb, and GlaxoSmithKline. Governance structures mirror models used by associations such as the Pharmaceutical Research and Manufacturers of America, featuring executive boards, technical committees, and special advisory groups with links to institutions like Conselho Nacional de Saúde. Leadership has included executives with prior roles at companies referenced in public records alongside engagement with regulatory bodies such as ANVISA and legislative committees of the Chamber of Deputies (Brazil).
Interfarma organizes conferences, workshops, and clinical research initiatives paralleling events by BIO (trade association) and PhRMA. Programs include capacity-building with universities like Universidade Federal do Rio de Janeiro and partnerships resembling collaborations between Fiocruz and industry. The association has promoted clinical trial registration practices comparable to the ClinicalTrials.gov model and supported pharmacovigilance dialogues involving agencies such as the Pan American Health Organization. Interfarma also facilitates industry participation in health technology assessment processes resembling those of the National Institute for Health and Care Excellence.
The association has taken positions on patent term extensions, data exclusivity, and regulatory timelines similar to debates in United States and European Union contexts, interacting with legal frameworks influenced by the TRIPS Agreement. Interfarma has lobbied National Congress of Brazil committees on legislation addressing compulsory licensing and price regulation, paralleling disputes involving Brazilian Ministry of Health procurement policies. It has submitted technical contributions to ANVISA consultations and engaged in public policy discussions about biosimilars in line with dialogues at the World Health Organization and regulatory decisions seen at the European Medicines Agency.
Critics have compared Interfarma's positions to corporate advocacy by organizations such as PhRMA and have contested its stances through civil society groups like Doctors Without Borders and national NGOs active in health policy. Controversies have centered on debates over access to essential medicines, patent enforcement, and price transparency, echoing tensions seen in cases involving Gilead Sciences and access campaigns in South Africa. Academic commentators and legislative actors have questioned industry influence on regulatory processes and public procurement, with references to contentious rulings in courts including the Supremo Tribunal Federal.
Interfarma has influenced investment flows and regulatory reform trajectories affecting pharmaceutical research similar to outcomes in markets engaged by INVEST Brazil and multinational firms such as Johnson & Johnson. Its advocacy contributed to shaping dialogue on clinical trials, regulatory harmonization, and intellectual property that intersect with institutions like ANVISA, Fiocruz, and the Ministry of Health (Brazil). While supporters credit the association with attracting R&D and promoting innovation networks with universities including Universidade de São Paulo and Campinas State University, opponents argue that its policy priorities may emphasize commercial interests comparable to debates in United States and European Union healthcare policy.
Category:Pharmaceutical industry associations Category:Organisations based in São Paulo Category:Healthcare in Brazil